What medication should be prescribed for a 15-year-old with substance use disorder, currently on Abilify (aripiprazole) 2 mg and Lexapro (escitalopram) 20 mg, who is irritable in an inpatient psychiatric setting?

Medication Management for Adolescent with Substance Use and Irritability

The current regimen of Abilify (aripiprazole) 2 mg should be discontinued or carefully reconsidered in this 15-year-old with active substance use, as recent evidence demonstrates aripiprazole may worsen compulsive substance use behaviors and is ineffective for substance use disorders. 1, 2

Critical Safety Concern with Current Aripiprazole Use

Aripiprazole poses a specific risk in patients with substance use history. The FDA label warns about pathological gambling and other compulsive behaviors 3, and emerging evidence from 2025 demonstrates that aripiprazole may actually increase urges and compulsive substance use in patients with substance use disorder history 2. Two case reports showed patients felt "unable to stop using, as if compelled to use substances" while on aripiprazole, with decreased urges after discontinuation 2.

Additionally, a 2025 systematic review provides strong evidence (Level of Evidence: strong) that aripiprazole is not effective for abstinence or decreased use in alcohol and stimulant use disorders, with some studies showing significant increases in stimulant consumption in the aripiprazole group 1. This carries a strong recommendation against use for substance use disorders 1.

Addressing the Irritability

For the acute irritability in this inpatient setting:

Short-term PRN management options based on pediatric inpatient data:

• Diphenhydramine (most commonly used, 26.4% of agitation doses in pediatric behavioral health units) 4
• Lorazepam (19% of doses) - though caution with substance use history 4
• Olanzapine (18.1% of doses) - better tolerated than aripiprazole in this context 4

These medications showed good tolerability with only 0.24% experiencing extrapyramidal symptoms, all managed with diphenhydramine 4.

Substance Use Disorder Treatment Considerations

For opioid use specifically (if applicable):

• Buprenorphine is FDA-approved for patients 16 years and older and recommended by the AAP for adolescents with severe opioid use disorders 5
• Naltrexone (extended-release) may be appropriate, particularly with co-occurring alcohol use, as it reduces both opioid and alcohol cravings 5

The AAP strongly advocates that pediatricians consider offering medication-assisted treatment or referral for adolescents with severe opioid use disorders 5.

Recommended Action Plan

1. Discontinue or taper aripiprazole 2 mg given the risk of worsening compulsive substance use behaviors
2. Continue Lexapro 20 mg - no contraindication identified
3. For acute irritability management: Use PRN diphenhydramine or olanzapam as first-line based on inpatient behavioral health data 4
4. Assess specific substances used: If opioids are involved and patient is 16+, initiate buprenorphine or consider naltrexone 5
5. Monitor closely for any impulse control problems if aripiprazole is continued despite recommendations 3, 2

Important Caveats

While one 2026 study suggested brexpiprazole may be superior to aripiprazole in schizophrenia patients with comorbid SUD 6, and another 2024 review suggested aripiprazole may reduce craving in dual diagnosis patients 7, these findings apply to patients with established severe psychiatric disorders (schizophrenia, schizoaffective disorder). The 2025 systematic review specifically excluded psychiatric comorbidities and found strong evidence against aripiprazole use 1. The irritability alone does not justify the substance use risks of continuing aripiprazole at this low dose.

The most concerning finding is that aripiprazole may paradoxically increase compulsive substance use through its effects on impulse control pathways 2, making it potentially harmful rather than neutral in this clinical scenario.